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Objective: to evaluate the beneﬁts of early diagnosis of cystic ﬁbrosis (CF) through
newborn screening (NS) in Sicily.
Study design: In our observational study we compared 95 screened (S) patients with
105 patients diagnosed by symptoms and/or familiarity (non-S patients), followed
in the CF Centers of Messina and Palermo, both for the risk of acquisition of
Pseudomonas aeruginosa, and for nutritional status during the ﬁrst 7 years of life.
Results: The S patients have a signiﬁcantly lower risk of chronic colonization with
Pseudomonas aeruginosa during the ﬁrst 7 years of life than the non-S patients.
They also have a lower risk of transient/intermittent infection from the 2nd year
of life, which becomes signiﬁcantly lower at the age of 5, 6 and 7 years. The S
patients have signiﬁcantly better weight and height z-scores than non-S patients at
5, 6 and 7 years of life, and better %p/h and BMI.
Conclusions: CF patients diagnosed early through NS and followed in the Sicilian
CF centers have a signiﬁcantly lower risk of chronic colonization with Pseudomonas
aeruginosa and better height and weight growth during the ﬁrst 7 years of life than
non-S patients.
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Newborn screening for CF has been available in Lombardy (Italy) since 1983
based on IRT/IRT strategy; in 1993 F508del analysis was included in the protocol,
and from 1998 the screening procedure combines IRT/IRT measurement and DNA
analysis of the most common CFTR mutations.
Recently, some studies reported a decreasing trend in the birth incidence of CF,
possibly justiﬁed by different factors such as accessibility of a prenatal diagnosis,
reproductive behaviours and population mixing.
Aim of this work was to determine the incidence of CF in Lombardy, a region
located in the north western part of Italy, nearby to the Veneto area were a decrease
of incidence has been observed.
The analysis was restricted to the period 2000 to 2007. We calculated the birth
incidence rate of CF in each year and in the overall study period, with corresponding
95% conﬁdence intervals (CI). We then assessed time trends in the incidence of CF
by Poisson regression, and calculated the average annual percent change (AAPC)
with its 95% CI. P-values <0.05 were considered signiﬁcant. On average, there were
about 90,000 births per year. Among the 717,172 newborns screened for CF within
the study period, 157 were found to have CF. The corresponding CF birth incidence
rate was 2.19 per 10,000 newborns (95%CI: 1.87−2.56). No signiﬁcant time trend
was observed in CF incidence in Lombardy over the study period (AAPC: −2.71%;
95%CI: −9.14% to +4.16%; p-value: 0.43).
In conclusion, CF birth prevalence appears to be stable in Lombardy.
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Diagnosis of cystic ﬁbrosis (CF) based on symptom presentation may give unreliable
data about CF prevalence cause some patients may still have to be detected. CF
Newborn screening (NBS) provide CF infants an early intervention and opportunity
to receive specialized medical care which reduce hospitalization and improves
survivals. CF NBS was introduced in Poland in September 2006. The program
currently covers 62% of Polish population. The screening protocol consists of IRT
analysis in two blood spots, followed by DNA testing and sweat chloride test in case
of IRT positive results. Molecular analysis, based on sequencing of 5 CFTR exons
(7, 10, 11, 13, 21), PCR (dele2,3) and PCR-RFLP (3849+10kbC>T) analysis, allows
identiﬁcation of 15 most frequent mutations in Polish population and about 370 rare
variants. Since September 2006 till the end of October 2008, 419 783 newborns were
screened by IRT. Of those, 2953 were screened for CFTR mutations. 264 infants
were positive; 61 had mutations in 2 alleles of CFTR gene and 59 of them were
conﬁrmed as having clinical symptoms of CF disease, 203 had mutation in 1 allele
with 7 of them presented clinical CF symptoms. The spectrum of CFTR variants
was signiﬁcantly different from the one previously reported in CF Polish patients,
diagnosed in postnatal procedure. We reported higher percentage of F508del allele
(70.30 vs 56%), identiﬁed 8 rare CFTR mutations previously not reported in Polish
CF patients and 6 completely new variants. Results of this program allowed us
to estimate provisionally frequency of CF in NBS in Poland (1/5119) and carrier
frequency (1/36) and in the future will help us to establish the CF epidemiology
and heterogeneity of CFTR mutations in Poland.
Supported by: Polish Ministry of Health.
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Background: CFTR F508del is considered to be severe mutation. Relations
between genotype and phenotype were many times reported. We tested whether
patients homozygous for F508del have earlier CF manifestation and different ﬁrst
symptoms compared to patients with alternative genetic background of CF. Also
the improvement of diagnostics was examined.
Methods: Data were obtained from 52 patients (Southern Moravia CF centre, from
1977 till 2008). Patients were divided into two groups: group of homozygotes
F508del with 26 subjects and group of other CFTR mutations with 26 subjects. Data
collected: year of birth, very ﬁrst symptom typical for CF mentioned in personal
history, very ﬁrst appearance of this symptom, time from CF manifestation to the
ﬁnal diagnosis.
Results: No statistical difference was found among two groups for time of
manifestation and initial symptoms. Group of other mutations has greater variability
of time of manifestation due to mild mutations included. Most common time
of ﬁrst CF symptom appearance is from 1 month to 16−20 months of age for
both groups. Typical ﬁrst symptom is malnutrition and rare fatty stools (49%),
followed by respiratory tract symptoms (34%), other symptoms are in minority
(18%). Diagnostics of CF in Southern Moravia has improved. During last 20 years
time from manifestation to ﬁnal diagnosis signiﬁcantly decreased.
